Diffuse Gastric Cancer

We live in an era of personalized medicine and the knowledge about pathophysiology of diffuse gastric cancer has had many advances. Thus, the role of this work is to clarify what is new from diagnosis to treatment of this disease in order to treat patients in the most tailored manner as possible.
Almost all phase III trials in gastric cancer have been performed without taking in consideration histologic subtypes, i.e. they have disregarded the differences between diffuse gastric cancer and general gastric cancer. However, the clinical practice reveals that diffuse gastric cancer is a completely distinct disease, with an aggressive course and generally worse prognosis. The loss of cohesion between tumor cells due to the loss of E-cadherin synthesis is the critical point on the oncogenesis of diffuse gastric cancer and is at the root of its marked heredity. This book intends to give special attention to Diffuse Gastric Cancer as a particular oncological entity, differentiating it from general gastric cancer, exploring and discussing all its peculiarities, and addressing the basic aspects (pathology and genetics) along with the most recent therapeutic alternatives for this condition.



Tiago Biachi de Castria,MD by the Federal University of Health Science of Porto Alegre (Brazil, 2009) and fellowship in Internal Medicine at the Federal University of São Paulo - UNIFESP (Brazil, 2012). From 2012 to 2015, was a fellow of Clinical Oncology at the School of Medicine of the University of São Paulo/State of São Paulo Cancer Institute (FMUSP/ICESP). PhD degree in Internal Medicine and Therapeutics at the UNIFESP (2013). He is currently a clinical oncologist at ICESP and Sírio Libanês Hospital, with focus on gastrointestinal malignancies.

Rodrigo Santa Cruz Guindalini  He pursued his medical degree (2000-2005) and did residency in Internal Medicine (2007-2009) at the Federal University of São Paulo (Brazil). Completed his Clinical Oncology fellowship (2009-2012) and attained the PhD degree in the field of Cancer Genetics (2012-2016) at the School of Medicine of the University of São Paulo/State of São Paulo Cancer Institute (FMUSP/ICESP) (Brazil). In the years 2012/2013 was a fellow at the MacLean Center for Clinical Medical Ethics and visiting scholar at The Center for Clinical Cancer Genetics and Global Health of the University of Chicago (USA). He is currently a postdoctoral research fellow with primary focus on hereditary cancer syndromes at the FMUSP/ICESP. In addition, he is the head of the Português Hospital/CLION Cancer Center (Brazil) and coordinator of the Center for Genetics and Cancer Prevention of Grupo CAM (Brazil).